---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-014547"
form_type: "8-K"
ticker: "PLSE"
cik: "0001625101"
company_name: "PULSE BIOSCIENCES, INC."
filed_at: "2026-05-04T23:59:59+00:00"
generated_at: "2026-05-14T23:55:12.268784+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Pulse Biosciences Q1 net loss $18.6M; accelerates NANOPULSE-AF enrollment to early Q4 2026

## Summary
- Preliminary Q1 2026: cash $68.3M, net loss $18.6M, cash used in ops $14.6M.
- Product revenue $0.4M; R&D $12.6M, SG&A $6.6M; costs up $1.6M YoY.
- NANOPULSE-AF U.S. IDE pivotal trial enrollment now expected to complete early Q4 2026.
- NANOCLAMP-AF surgical trial enrollment target: end of H1 2027.
- Added Dr. David Kenigsberg as full-time CMO and Liane Teplitsky as COO.

## SEC filing metadata
- accession: 0001437749-26-014547
- form_type: 8-K
- ticker: PLSE
- cik: 0001625101
- company_name: PULSE BIOSCIENCES, INC.
- filed_at: 2026-05-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625101/000143774926014547/0001437749-26-014547-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625101/000143774926014547/plse20260312_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-014547
- JSON: https://secwatch.observer/filing/0001437749-26-014547.json
- Plain text: https://secwatch.observer/filing/0001437749-26-014547.txt

## Key facts
- Earnings Releases
  PULSE BIOSCIENCES, INC. reported the first quarter ended March 31, 2026 results: revenue $0.4 million, net income ($18.6) million.
  - Period: the first quarter ended March 31, 2026
  - Revenue: $0.4 million
  - Net income: ($18.6) million
  - Result: reported results
  source text: Total revenue for the three months ended March 31, 2026 was $0.4 million, including both capital and disposable sales. Total GAAP costs and expenses, representing cost of product revenue, research and development, and selling, general and administrative expenses, for the three months ended March 31, 2026, were $19.6 million, an increase of $1.6 million compared to $18.0 million in the prior year period. The increase was primarily driven by increased investment in clinical programs, partially offset by lower stock-based compensation expense. Non-GAAP costs and expenses for the three months ended March 31, 2026, were $17.4 million, an increase of $4.7 million compared to $12.7 million in the prior year period. GAAP net loss for the three months ended March 31, 2026 was ($18.6) million compared to ($16.8) million for the three months ended March 31, 2025. Non-GAAP net loss for the three months ended March 31, 2026 was ($16.4) million compared to ($11.4) million for the three months ended
  evidence_url: https://www.sec.gov/Archives/edgar/data/1625101/000143774926014547/0001437749-26-014547-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.